Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$453M |
| 2 |
CELG
Celgene Corp
CELG
|
+$391M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$389M |
| 4 |
GE Aerospace
GE
|
+$378M |
| 5 |
Johnson & Johnson
JNJ
|
+$356M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UnitedHealth
UNH
|
+$307M |
| 2 |
Costco
COST
|
+$279M |
| 3 |
Lowe's Companies
LOW
|
+$273M |
| 4 |
Microsoft
MSFT
|
+$230M |
| 5 |
Chevron
CVX
|
+$225M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.07% |
| 2 | Technology | 14.35% |
| 3 | Financials | 11.23% |
| 4 | Consumer Discretionary | 9.93% |
| 5 | Real Estate | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2551
Caesarstone
CSTE
$116M
| $1.35M | ﹤0.01% |
+90,164
| New | +$1.35M |
|
|
LOAN
2552
Manhattan Bridge Capital
LOAN
$47.3M
| $1.35M | ﹤0.01% |
211,702
-26,400
| -11% | -$162K |
|
|
GVP
2553
DELISTED
GSE Systems, Inc.
GVP
| $1.35M | ﹤0.01% |
57,916
+496
| +0.9% | +$12.2K |
|
2554
InfuSystem Holdings
INFU
$243M
| $1.35M | ﹤0.01% |
314,722
+830
| +0.3% | +$3.85K |
|
2555
State Street SPDR US Large Cap Low Volatility Index ETF
LGLV
$1.23B
| $1.35M | ﹤0.01% |
+12,500
| New | +$1.3M |
|
2556
MIND Technology
MIND
$42.4M
| $1.34M | ﹤0.01% |
33,982
+2,212
| +7% | +$84.8K |
|
2557
Consumer Portfolio Services
CPSS
$208M
| $1.34M | ﹤0.01% |
352,909
+26,302
| +8% | +$93.5K |
|
|
LORL
2558
DELISTED
Loral Space and Communications, Inc.
LORL
| $1.34M | ﹤0.01% |
38,769
+17,769
| +85% | +$643K |
|
|
BFX
2559
DELISTED
BowFlex Inc.
BFX
| $1.33M | ﹤0.01% |
+604,200
| New | +$2.38M |
|
|
CSS
2560
DELISTED
CSS Industries, Inc.
CSS
| $1.33M | ﹤0.01% |
272,019
+36,349
| +15% | +$212K |
|
|
FRTX
2561
DELISTED
Fresh Tracks Therapeutics, Inc. Common Stock
FRTX
| $1.32M | ﹤0.01% |
4,945
-129
| -3% | -$43.2K |
|
2562
Gentherm
THRM
$1.34B
| $1.32M | ﹤0.01% |
31,564
+19,064
| +153% | +$767K |
|
2563
Princeton Bancorp
BPRN
$295M
| $1.31M | ﹤0.01% |
43,623
+8,019
| +23% | +$238K |
|
2564
Denali Therapeutics
DNLI
$3.9B
| $1.31M | ﹤0.01% |
+63,000
| New | +$1.41M |
|
|
SEM
2565
DELISTED
Select Medical
SEM
| $1.3M | ﹤0.01% |
152,563
-160,730
| -51% | -$1.27M |
|
|
BOCH
2566
DELISTED
Bank of Commerce Holdings (CA)
BOCH
| $1.3M | ﹤0.01% |
122,100
-10,400
| -8% | -$111K |
|
2567
First US Bancshares
FUSB
$90.8M
| $1.3M | ﹤0.01% |
140,664
+10,320
| +8% | +$100K |
|
2568
Tennant Co
TNC
$1.18B
| $1.3M | ﹤0.01% |
21,200
-2,700
| -11% | -$168K |
|
|
SRRA
2569
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| $1.29M | ﹤0.01% |
57,816
+10,433
| +22% | +$505K |
|
2570
PennyMac Financial
PFSI
$4.08B
| $1.29M | ﹤0.01% |
58,100
-10,245
| -15% | -$228K |
|
|
HUSN
2571
DELISTED
Hudson Capital Inc. Ordinary Shares
HUSN
| $1.29M | ﹤0.01% |
282,785
+28,511
| +11% | +$153K |
|
2572
Neurocrine Biosciences
NBIX
$15.5B
| $1.29M | ﹤0.01% |
15,241
-212,700
| -93% | -$17.5M |
|
|
PBFX
2573
DELISTED
PBF LOGISTICS LP
PBFX
| $1.28M | ﹤0.01% |
60,600
+9,100
| +18% | +$188K |
|
2574
W.R. Berkley
WRB
$26.2B
| $1.28M | ﹤0.01% |
43,538
-1,337,512
| -97% | -$36.6M |
|
|
LOMA
2575
Loma Negra
LOMA
$1.09B
| $1.27M | ﹤0.01% |
108,612
+78,912
| +266% | +$831K |
|
Similar funds
Jim Simons's Q2 2019 Portfolio in Review
As of Q2 2019, Jim Simons held 3,913 positions worth $114B, up 3.3% from $110B the previous quarter. Its ten largest holdings account for 9.1% of the portfolio.
Jim Simons's Q2 2019 filing shows 495 new, 1,847 increased, 1,145 reduced and 397 closed positions. Its largest new stake was Apple: 9,290,160 shares worth $460M. The largest sale was UnitedHealth, an estimated $307M.
By sector, the portfolio is most concentrated in Healthcare at 18% of assets, up from 17% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q2 2019 buy was Apple: 9,290,160 shares worth $460M.
- Jim Simons added most to Celgene Corp in Q2 2019, an estimated $391M increase.
- Jim Simons's biggest Q2 2019 reduction was Microsoft, cutting an estimated $230M.
- Jim Simons fully exited UnitedHealth in Q2 2019, selling an estimated $307M.
- Jim Simons's ten largest holdings make up 9.1% of its $114B portfolio in Q2 2019.
- Jim Simons opened 495 new positions and closed 397 in Q2 2019.
- Jim Simons's portfolio value rose 3.3% quarter-over-quarter to $114B.
Based on Renaissance Technologies's 13F filing for Q2 2019, filed 12 Aug 2019.